A PHASE 1, OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY, AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER T (INKT) CELLS (AGENT-797) AS A SINGLE AGENT AND IN COMBINATION WITH APPROVED IMMUNE CHECKPOINT INHIBITORS IN SUBJECTS WITH RELAPSED/REFRACTORY SOLID TUMORS
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Breelyn Wilky, MD
Study ID
Protocol Number: 22-0878
More information available at ClinicalTrials.gov: NCT05108623
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers